50740-12-0

Basic information

• Product Name: Benzoyl chloride, 2,4-bis(acetyloxy)-
• CAS NO: 50740-12-0
• Molecular Formula: C11H9ClO5
• Molecular Weight: 256.642
• Mol File: 50740-12-0.mol
• Article Data: 12

Chemical Properties

• CAS DataBase Reference: Benzoyl chloride, 2,4-bis(acetyloxy)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoyl chloride, 2,4-bis(acetyloxy)-(50740-12-0)
• EPA Substance Registry System: Benzoyl chloride, 2,4-bis(acetyloxy)-(50740-12-0)

Safety Data

• Hazardous Substances Data: 50740-12-0(Hazardous Substances Data)

Upstream product

• 89-86-1 4-hydroxysalicylic acid 
• 51-01-4 2,4-bis(acetyloxy)benzoic acid 

Downstream Products

• 195723-45-6 N-(4-methyl)phenyl-2,4-diacetoxybenzamide 
• 55981-14-1 Acetic acid 5-acetoxy-2-(5-nitro-thiazol-2-ylcarbamoyl)-phenyl ester 

Relevant articles and documents

Structure-Activity Study of Nitazoxanide Derivatives as Novel STAT3 Pathway Inhibitors

We identified nitazoxanide (NTZ) as a moderate STAT3 pathway inhibitor through immunoblot analysis and a cell-based IL-6/JAK/STAT3 pathway activation assay. A series of thiazolide derivatives were designed and synthesized to further validate the thiazolide scaffold as STAT3 inhibitors. Eight out of 25 derivatives displayed potencies greater than that of NTZ, and their STAT3 pathway inhibitory activities were found to be significantly correlated with their antiproliferative activities in HeLa cells. Derivatives 15 and 24 were observed to be more potent than the positive control WP1066, which is under phase I clinical trials. Compared with NTZ, 15 also exhibited much improved in vivo pharmacokinetic parameters in rats and efficacies against proliferations in multiple cancer cell lines, indicating a broad-spectrum effect of these thiazolides as antitumor agents targeted on STAT3.

Synthesis and Biological Evaluation of Amide-Type Phytoalexins as Depigmenting Agents

-

TETRAHYDROISOQUINOLINE COMPOUNDS AND THEIR USE AS PYRUVATE DEHYDROGENASE KINASE INHIBITORS

A compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein: R1 is H, Cl, F, CH3 or CF3; R2 is H, C1-C6 alkyl or optionally substituted heteroaryl or optionally substituted aryl; and R3 is (Alk)n-Rn-(Alk)n-Rn-(Alk)n-X. The compounds are useful as tetrahydroisoquinoline (THQ) compounds, which are suitable for use as PDK inhibitors, for example for inhibition of cancer cell proliferation.